• Explore /
  • Poster
  • / Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303).

Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303).

Abstract Poster

Authors

null

Karen L. Reckamp

City of Hope National Medical Center, Duarte, CA

Karen L. Reckamp , Paul Henry Frankel , Philip C Mack , Barbara Jennifer Gitlitz , Nora Ruel , Primo Lara Jr., Tianhong Li , Marianna Koczywas , Shirish M. Gadgeel , Mihaela C. Cristea , Chandra Prakash Belani , Edward M. Newman , David R. Gandara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01866410

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 8014)

DOI

10.1200/jco.2014.32.15_suppl.8014

Abstract #

8014

Poster Bd #

28

Abstract Disclosures

Similar Posters

First Author: Chul Kim

First Author: Karen L. Reckamp

First Author: Bartomeu Massuti

First Author: Primo Lara Jr.